Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 13, 2004 - Issue 8
Submit an article Journal homepage
64
Views
20
CrossRef citations to date
0
Altmetric
Review

Rheumatoid arthritis: developing pharmacological therapies

Joel D Abbott University of Alabama at Birmingham, Department of Medicine; Division of Clinical Immunology and Rheumatology, 1717 6th Avenue South, SRC 068, Birmingham, AL 35294-7201, USA. [email protected]
&
Larry W Moreland University of Alabama at Birmingham, Department of Medicine; Division of Clinical Immunology and Rheumatology, 1717 6th Avenue South, SRC 068, Birmingham, AL 35294-7201, USA. [email protected]
Pages 1007-1018 | Published online: 24 Feb 2005

Bibliography

  • HOCHBERG MC, SPECTOR TD: Epidemiology of rheumatoid arthritis: update. Epideiniol Rev (1990) 12:247–252.
  • CHOY EHS, PANAYI GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl. I Med (2001) 344:907–916.
  • •An excellent overview of the pathogenetic role of various proinflamrnatory cytokines in RA and approaches to their inhibition.
  • PANAYI GS, LANCHBURY JS, KINGSLEY GH: The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritic Rheum. (1992) 35:729–735.
  • COHEN S, CANNON GW, SCHIFF M et al.: Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Investigator Group. Arthritic Rheum. (2001) 44:1984–1992.
  • KLARESKOG L, VAN DER HEIJDE D, DE JAGER JP et al.: Therapeutic effect of the combination of etanercept and compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial (TEMPO). Lancet (2004) 363:675–681.
  • MUELLER DL, JENKINS MK, RH: Clonal expansion versus functional clonal inactivation: a costimulatory signaling pathway determines the outcome of T cell antigen receptor occupancy. Ann. Rev. Immunol (1989) 7:445–480.
  • KOULOVA L, CLARK EA, SHU G, DUPONT B: The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells.' Exp. Med. (1991) 173:759–762.
  • LINSLEY PS, GREENE JL, BRADY W, BAJORATH J, LEDBETTER JA, PEACH R: Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity (1994) 1:793–801.
  • VERWILGHEN J, LOVIS R, DE M et al.: Expression of functional B7 and CTLA4 on rheumatoid synovial T cells. J.Immunol. (1994) 153:1378–1385.
  • MIHARA M, TAN I, CHUZHIN Y et aL: CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus.J. Clin. Invest. (2000)106:91–101.
  • WEBB LM, WALMSLEY MJ, FELDMANN M: Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur.j Immunol (1996) 26:2320–2328.
  • QUATTROCCHI E, DALLMAN MJ, FELDMANN M: Adenovitus-mediated gene transfer of CTLA-41g fusion protein in the suppression of experimental autoimmune arthritis. Arthritis Rheum. (2000) 43:1688–1697.
  • ABRAMS JR, LEBWOHL MG, CA et al.: CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. Clin. Invest. (1999) 103:1243–1252.
  • ABRAMS JR, KELLEY SL, HAYES E et al:Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. Exp. Med. (2000) 192:681–693.
  • MORELAND LW, RIEKE A, DEN BOSCH F et al: Costimulatory in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind,controlled trial evaluating CTLA-4Ig and LEA29Y eight-five days after the first infusion. Arthritis Rheum. (2002) 46:1470–1479.
  • KREMER JM, WESTHOVENS R, LEON M et al.: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl. J. Med. (2003) 349:1907–1915.
  • ••A Phase IIb study evaluating CTLA4Ig incombination with methotrexate. A greater proportion of patients treated with CTLA4Ig and methotrexate met ACR20 response criteria than those treated with methotrexate alone.
  • ZHANG Z, BRIDGES SL: Pathogenesis ofrheumatoid arthritis: role of B lymphocytes. Rheum. Dis. Clin. North Am. (2001) 27:335–353.
  • VAN ZEBEN D, HAZES JMW, ZWINDERMAN AH et al.: Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow-up study. Ann. Rheum. Dis. (1992) 51:1029–1035.
  • SCHELLEKENS GA, VISSER H, DE JONG BAW et al.: The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. (2000) 43:155–163.
  • VAN GAALEN FA, LINN-RASKER SP, VAN VENROOIJ WJ et al: Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum. (2004) 50:709–715.
  • TAKEMURA S, KLIMIUK PA, BRAUN A, GORONZY JJ, CM: T cell activation in rheumatoid synovium is B cell dependent. (2001) 167:4710–4718.
  • •In this study, CD4+ T cells isolated from human rheumatoid synoviurn failed to enhance cytokine production when transferred into RA synovium-SCID mouse chimeras in the absence of B cells suggesting a pivotal role for B cells in the pathogenesis of RA.
  • RASTETTER W, MOLINA A, CA: Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Ann. Rev Med. (2004) 55:477–503.
  • LEANDRO MJ, EDWARDS JC, CAMBRIDGE G, EHRENSTEIN MR, ISENBERG DA: An open study of lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. (2002) 46:2673–2677.
  • STASI R, PAGANO A, STIPA E, AMADORI S: Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenia purpura. Blood (2001) 98:952–957.
  • ZHENG X, PALLERA AM, GOODNOUGH LT, SADLER E, BLINDER MA: Remission of chronic thrombotic thrombocytopenia purpura after treatment with cyclophosphamide and rituximab. Ann. Intern. Med. (2003) 138:105–108.
  • PERROTTA S, LOCATELLI F, LA MANNA A, CENNAMO L, STEFANO P, NOBILI B: Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br. J. HaematoL (2002) 116:465–467.
  • EDWARDS JCW, CAMBRIDGE G: Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (2001) 40:205–211.
  • LEANDRO MJ, EDWARDS JCW, CAMBRIDGE G: Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann. Rheum. Dis. (2002) 61:883–888.
  • •In this study, 22 patients with active RA were randomised to one of five treatment groups receiving rituximab in varying doses in combination with cydophospharnide and or prednisolone. A higher proportion of patients treated with rituximab and cyclophospharnide experienced improvement (by ACR criteria).
  • EDWARDS JCW, LESZEK S, SZECHINSKI J et al.: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Eng. I Med. (2004) 350:2572–2581.
  • •In this Phase II trial, 161 refractory RA patients were randomised to one of four treatment groups receiving rituximab alone or in combination with methotrexate or cydophospharnide versus methotrexate alone. A higher proportion of patients treated with rituximab reached an ACR50 response than those treated with methotrexate alone.
  • DE VITA S, ZAJA F, SACCO S, DE CANDIA A, FANIN R, FERRACCIOLI G: Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritic Rheum. (2002) 46:2029–2033.
  • CAMBRIDGE G, LEANDRO MJ, EDWARDS JCW et al.: Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. (2003) 48:2146–2154.
  • McLAUGHLIN P, HAGEMEISTER FB, GRILLO-LOPEZ AJ: Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin. Oncol (1999) 26\(Suppl. 14):79–87.
  • SHAW T, QUAN J, TOTORITIS MC: B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann. Rheum. Dis. (2003) 62(Suppl. II):fi55-fi59.
  • MAINI R, ST CLAIR EW, VELD F et al.: Infliximab (chimeric anti-tumor necrosis factor-a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized Phase III trial. Lancet (1999) 354:1932–1939.
  • MAINI R, BREEDVELD FC, JR et al.: Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. (2004) 50:1051–1065.
  • MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N EngL I Med. (1997) 337:141–147.
  • KEYSTONE EC, KAVANAUGH AF, SHARP JT et al.: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. (2004) 50:1400–1411.
  • BRESNIHAN B, ALVARO-GRACIA JM, COBBY M et al.: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. (1998) 41:2196–2204.
  • DAYER JM: The pivotal role of interleukin-1 in the clinical manifestations rheumatoid arthritis. Rheumatology (2003) 42\(Suppl. 2):ii3–1110.
  • DINARELLO CA: Interleuldn-1(3, interleukin-18, and the interleukin-1I3 converting enzyme. Ann. NY Acad. Sri. (1998) 856:1–11.
  • WESCHE H, KORHERR C, KRACHT M et al.: The interleukin-1 receptor accessory protein is essential for IL-1-induced activation of interleukin-1 receptor-associated kinase and stress-activated protein kinases. Biol. Chem. (1997) 272:7727–7731.
  • COLOTTA F, DOWER SK, SIMS JE, MANTOVANI A: The type II 'decoy' receptor: a novel regulatory pathway for interleukin 1. Immunol Today (1994) 15:562–566.
  • VAN DEN BERG WB, JOOSTEN LA, HELSEN M, VAN DE LOO FA: Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin. Exp. brimunol. (1994) 95:237–243.
  • COHEN S, HURD E, CUSH Jet al.: Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2002) 46:614–624.
  • HAWKINS PN, LACHMANN HJ, AGANNA E, MCDERMOTT MF: Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Athritis Rheum. (2004) 50:607–612.
  • TESSER J, FLEISCHMANN R, DORE R et al.: Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis. (2004) 31:649-654.
  • ECONOMIDES AN, CARPENTER LR, RUDGE JS: Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat. Med. (2003) 9:47–52.
  • GULER HP, CALDWELL JR, FLEISCHMAN RIVI et al.: Weekly treatment with IL-I Trap is well tolerated and improves ACR criteria in patients with active rheumatoid arthritis. Annual European Congress of Rheumatology EULAR 2002. Stockholm, Sweden (2002) (Abstract OP0090).
  • KU G, FAUST T, LAUFFER LL, LIVINGSTON DJ, HARDING MW: Interleukin-i13 converting enzyme inhibition blocks progression of Type II collagen-induced arthritis in mice. Cytokine (1996) 8:377–386.
  • PAVELKA K, KUBA V, RASMUSSEN JM et al.: Clinical effects of pralnacasan (PRAL), an orally-active interleukin-1B converting enzyme (ICE) inhibitor, in a 285 patient Phase II trial in rheumatoid arthritis. American College of Rheumatology 66th Annual Scientific Meeting. New Orleans, USA (2002) (Abstract LB02).
  • CHOY E: Interleuldn 6 receptor as a targetfor the treatment of rheumatoid arthritis. Ann. Rheum. Dis. (2003) 62 (Suppl. II):1168–1169.
  • BOE A, BAIOCCHI M, M, PAPOIAN R, SERLUPI-CRESCENZI 0: Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis. Cytokine. (1999) 11:1057–1064.
  • TAKAGI N, MIHARA M, MORIYA Y et al.: Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum. (1998) 41:2117–2121.
  • MIHARA M, KOTOH M, NISHIMOTO N et al: Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys. Clin. Immunol (2001) 98:319–326.
  • WENDLING D, RACADOT E, WIJDENES J: Treatment of severe rheumatoid arthritis by and-interleukin 6 monoclonal antibody. Rheumatol (1993) 20:259–262.
  • CHOY EHS, ISENBERG DA, T et al.: Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis. Arthritis Rheum. (2002) 46:3143–3150.
  • NISHIMOTO N, YOSHIZAKI K, MIYASAKA N et al.: Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. (2004) 50:1761–1769.
  • NISHIMOTO N, YOSHIZAKI K, MIYASAKA N et al.: Long-term safety and efficacy of anti-interleukin 6 receptor antibody (MRA) in patients with rheumatoid arthritis. American College of 67th Annual Scientific Meeting. Orlando, USA (2003) (Abstract 216).
  • MAINI RN, TAYLOR PC, PAVELKA K et al.: Efficacy of IL-6 receptor antagonist MRA in rheumatoid arthritis patients with an incomplete response to methotrexate (CHARISMA). American College of Rheumatology 67th Annual Scientific Meeting, Orlando, USA (2003) (Abstract 1704).
  • MAINI RN, TAYLOR PC, PAVELKA K et al.: (CHARISMA Study Group): a double-blind, randomised, parallel group, controlled, dose ranging study of the safety, tolerability, pharmacokinetics and efficacy of repeat doses of MRA given alone or in combination with methotrexate in patients with rheumatoid arthritis. Annual European Congress of Rheumatology EULAR 2003. Lisbon, Portugal (2003) (Abstract 0P0002).
  • McINNES IB, GRACIE JA, M, HARNETT W, LIEW FY: New strategies to control inflammatory synovitis: interleukin-15 and beyond. Ann. Rheum. Dis. (2003) 62 (Suppl. ii):ii51-ii54.
  • FERRARI-LACRAZ S, ZHENG XX, SU KIM Y et al.: An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection. brimunol. (2001) 167:3478–3485.
  • SU KIM Y, MASLINSKI W, ZHENG XX et al.: Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fcy2a protein blocks delayed-type hypersensitivity.. (1998) 160:5742–5748.
  • RUCHATZ H, LEUNG BP, WEI X, MCINNES IB, LIEW FY: Soluble IL-15 receptor-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology.j. Immunol (1998) 160:5654–5660.
  • BASLUND B, TVEDE N,-SAMSOE B et al: A novel human monoclonal antibody against IL-15 (humax-IL15) in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled Phase I/II trial. American College of Rheumatology 67th Annual Scientific Meeting. Orlando, USA (2003) (Abstract 1706).
  • LIEW FY, WEI X, McINNES IB: Role of interleukin 18 in rheumatoid arthritis. Ann. Rheum. Dis. (2003) 62\(Supp1.11):1i48-1i50.
  • JOOSTEN LAB, RADSTAKE TRD, LUBBERTS E et al.: Association of-18 expression with enhanced levels of both interleukin-113 and tumor necrosis factor-a in knee synovial tissue of patients with rheumatoid arthritis. Arthritic Rheum. (2003) 48:339–347.
  • •In this study, biopsy specimens of knee synovial tissue were obtained from 29 patients with active RA. Expression of IL-18 in the synovial tissue was found to be associated with expression of 11–113 and TNF-a suggesting a primary proinflarnrnatory role for IL-18 in RA.
  • PLATER-ZYBERK C, JOOSTEN LAB, HELSEN MMA et al: Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis.. Invest. (2001) 108:1825–1832.
  • SMEETS RL, VAN DE LOO FAJ, ARNTZ 0J, BENNICK MB, JOOSTEN LAB, VAN DEN BERG WB: Adenoviral delivery of IL-18 binding protein C ameliorates collagen-induced arthritis in mice. Gene Therapy (2003) 10:1004–1011.
  • SHANAHAN JC, MORELAND LW, CARTER RH: Upcoming biologic agents for the treatment of rheumatic diseases. Cup-. Opin. Rheumatol (2003) 15:226–236.
  • CHOY EHS, HAZLEMAN B, SMITH M et al.: Efficacy of a novel PEGylated humanized antiTNF fragment (CDP870) in patients with rheumatoid arthritis: a Phase II double-blinded, randomized, dose-escalating trial. Rheumatology (2002) 41:1133–1137.
  • BUSH KA, WALKERJS, FRAZIER J, KIRKHAM BW: Effects of a PEGylated soluble TNF receptor Type 1 (PEG sTNF-R1) on cytokine expression in adjuvant arthritis. Scand.j. Rheumatol (2002) 31:198–204.

Websites

  • http://www.regeneron.com/company/ press_detaiLasp?v_c_id=184 reports Phase II results for IL-1 clinical programme in rheumatoid arthritis: IL-1 trap Phase II study clinical activity and favourable safety and tolerability profile (2003).
  • http://www.vpharm.com/Pressreleases 192003/ pr111003av.html and Vertex Pharmaceuticals voluntarily discontinue Phase IIb clinical trials of pralnacasan in rheumatoid arthritis: Phase II activities temporarily suspended while unexpected toxicology results analysed (2003).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.